Industry: Pharmaceuticals (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2024-08-02 | New | $2,296,880 | $2,296,880 | Equity Only | 06b | SEC link |
| 2024-06-11 | New | $2,077,409 | $2,077,409 | Equity Only | 06b | SEC link |
| 2021-02-22 | New | $4,276,000 | $4,276,000 | Equity Only | 06b | SEC link |
| 2020-05-08 | New | $2,399,500 | $2,399,500 | Equity Only | 06b | SEC link |
| 2019-12-18 | New | $115,000 | $115,000 | Equity Only | 06b | SEC link |
| 2018-12-18 | New | Yet to Sell | $0 | Equity Only | 06b | SEC link |
| 2014-07-07 | New | $435,000 | $435,000 | Equity Only | 06b | SEC link |
| 2013-10-11 | Amended | $1,000,000 | $1,000,000 | Equity Only | 06b | SEC link |
| 2013-06-07 | New | Yet to Sell | $0 | Equity Only | 06 | SEC link |
| 2011-11-22 | New | $6,560 | $6,560 | Equity Only | 04.1 | SEC link |
| Name | Role |
|---|---|
| Richard A. Brand | Director, Executive |
| Wayne Linsley | Director |
| Vadim Mats | Executive |
| Kevin Munoz | Director |
| Van Parker | Director |
| Jeff Pavell | Director |
| Daniel Ryweck | Executive |
| Leonard Schiller | Director |
| Melvin Schlossberg | Director, Executive |
| Joel Stone | Director |
| Eric Weisblum | Director, Executive |